Effect of Saccharomyces boulardii in dogs with chronic enteropathies: double-blinded, placebo-controlled study

2017 ◽  
Vol 182 (9) ◽  
pp. 258-258 ◽  
Author(s):  
Simona D’Angelo ◽  
Federico Fracassi ◽  
Francesca Bresciani ◽  
Roberta Galuppi ◽  
Alessia Diana ◽  
...  
Keyword(s):  
Body Condition Score ◽  
Activity Index ◽  
Clinical Signs ◽  
Saccharomyces Boulardii ◽  
Controlled Study ◽  
Clinical Activity ◽  
Short Term ◽  
Chronic Enteropathies ◽  
Healthy Dogs ◽  
Double Blinded

Saccharomyces boulardii is used to treat acute and chronic enteropathies in humans, but to date, no studies have evaluated the use of this yeast in dogs. The current study, a prospective non-randomised, double-blinded, placebo-controlled study, evaluated the effects of S boulardii in healthy dogs and dogs with chronic enteropathies (CE). Four healthy dogs and 20 dogs with CE were included. In healthy dogs, S boulardii was administered for 10 days. Possible short-term adverse effects were recorded, and quantitative stool cultures for yeasts were performed. In dogs with CE, S boulardii or a placebo was administered in addition to standard treatment protocols. Canine Chronic Enteropathy Clinical Activity Index, abdominal ultrasonography, gastroenteroscopy and histology were performed at the time of diagnosis and after 60 days of treatment. In healthy dogs, S boulardii reached a steady state in five days and was completely eliminated on day 4 after administration. No short-term side effects were seen. Clinical activity index, stool frequency, stool consistency and body condition score improved significantly in dogs with CE receiving S boulardii versus the placebo. In conclusion, S boulardii can be safely used in dogs with CE and seems to achieve better control of clinical signs than standard therapy alone.

scholarly journals The Impact of Chronic Inflammatory Enteropathy on Dogs’ Quality of Life and Dog-Owner Relationship

2021 ◽  
Vol 8 (8) ◽  
pp. 166
Author(s):  
Veronica Marchetti ◽  
Eleonora Gori ◽  
Valeria Mariotti ◽  
Angelo Gazzano ◽  
Chiara Mariti
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Activity Index ◽  
Control Group ◽  
Clinical Activity ◽  
Chronic Enteropathies ◽  
Healthy Dogs ◽  
The Impact

This research was aimed at evaluating the impact of canine chronic enteropathies on dogs’ quality of life (QoL), their behavior, and owner–dog relationship. Forty-four dogs suffering from primary chronic enteropathies were assessed on the first visit with a veterinary gastroenterologist and on the first follow-up visit using a 1–10 visual scale to evaluate five features of QoL, the Canine Chronic Enteropathy Clinical Activity Index, the Lexington Attachment to Pet Scale, and the Canine Behavioral Assessment and Research Questionnaire. They were compared to a control group of 49 healthy dogs and to a group of 50 dogs suffering from cancer. QoL and severity of enteropathy were negatively associated; enteropathic dogs on the first visit had a lower QoL than healthy dogs for all features and a lower general QoL than cancer patients; enteropathic dogs on the follow-up visit improved significantly for general QoL, health QoL, and interaction QoL. Higher levels of attachment between the owner and the dog were obtained for dogs affected by chronic enteropathies. Finally, dogs showed higher scores for separation-related behaviors and contact/attention behaviors on the first visit than on the subsequent follow-up. As in human medicine, chronic enteropathies have a strong negative impact on dogs.

COMPARISON OF ULTRASONOGRAPHIC FINDINGS WITH CLINICAL ACTIVITY INDEX (CIBDAI) AND DIAGNOSIS IN DOGS WITH CHRONIC ENTEROPATHIES

2008 ◽  
Vol 49 (1) ◽  
pp. 56-64 ◽  
Author(s):  
LORRIE GASCHEN ◽  
PATRICK KIRCHER ◽  
ANJA STÜSSI ◽  
KARIN ALLENSPACH ◽  
FRÉDÉRIC GASCHEN ◽  
...  
Keyword(s):  
Activity Index ◽  
Clinical Activity ◽  
Chronic Enteropathies

scholarly journals Comparison of Short- versus Long-Course Antimicrobial Therapy of Uncomplicated Bacterial Pneumonia in Dogs: A Double-Blinded, Placebo-Controlled Pilot Study

Animals ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 3096
Author(s):  
Aida I. Vientós-Plotts ◽  
Isabelle Masseau ◽  
Carol R. Reinero
Keyword(s):  
Pilot Study ◽  
Antimicrobial Therapy ◽  
Bacterial Pneumonia ◽  
Clinical Signs ◽  
Current Treatment ◽  
Controlled Study ◽  
Primary Study ◽  
Study Objective ◽  
Primary Study Objective ◽  
Double Blinded

Current treatment for canine bacterial pneumonia relies on protracted courses of antimicrobials (3–6 weeks or more) with recommendations to continue for 1–2 weeks past resolution of all clinical and thoracic radiographic abnormalities. However, in humans, bacterial pneumonia is often treated with 5–10-day courses of antimicrobials, and thoracic radiographs are not considered useful to guide therapeutic duration. The primary study objective was to determine whether a short course of antimicrobials would be sufficient to treat canine bacterial pneumonia. Eight dogs with uncomplicated bacterial pneumonia were enrolled in this randomized, double-blinded, placebo-controlled study comparing clinical and radiographic resolution with differing durations of antimicrobial therapy. Dogs received a course of antimicrobials lasting 10 (A10) or 21 (A21) days. Dogs randomized to the A10 group received placebo for 11 days following antimicrobial therapy. Patients were evaluated at presentation and 10, 30 and 60 days after the initiation of antimicrobials. At 10 days, 6/8 dogs had resolution of both clinical signs and inflammatory leukogram, and 5/8 dogs had improved global radiographic scores. After 60 days, clinical and hematologic resolution of pneumonia was noted in all dogs regardless of antimicrobial therapy duration; however, 3/8 dogs had persistent radiographic lesions. Thoracic radiographs do not appear to be a reliable marker to guide antimicrobial therapy in canine bacterial pneumonia as radiographic lesions may lag or persist despite clinical cure. This pilot study suggests a 10-day course of antimicrobials may be sufficient to treat uncomplicated canine bacterial pneumonia.

scholarly journals Plasma insulin-like growth factor-1 concentration in dogs with chronic enteropathies

2012 ◽  
Vol 51 (No. 1) ◽  
pp. 35-43
Author(s):  
Spichiger AC ◽  
K. Allenspach ◽  
Y. Zbinden ◽  
Doherr MG ◽  
S. Hiss ◽  
...  
Keyword(s):  
Growth Factor ◽  
Activity Index ◽  
Plasma Concentrations ◽  
Clinical Score ◽  
Insulin Like Growth Factor ◽  
Disease Group ◽  
Before And After ◽  
Chronic Enteropathies ◽  
Inflammatory Bowel ◽  
Healthy Dogs

Plasma concentrations of insulin-like growth factor (IGF)-1 were examined in dogs suffering from food-responsive diarrhea (group FRD) or inflammatory bowel disease (group IBD) before and after treatment and compared with IGF-1 values in healthy dogs (group C). Blood of 76 dogs was sampled (FRDbefore treatment, n = 23; IBD before treatment, n = 11; C, n = 42) and after treatment (FRD, n = 15; IBD, n= 8) with a hypoallergenic diet combined with (group IBD) or without prednisolone (group FRD). A clinical score (Canine IBD Activity Index = CIBDAI) was applied to judge the health status in all dogs. Plasma concentration of IGF-1, of total protein, albumin, glucose, urea, non-esterified fatty acids (NEFA), and of the acute phase protein haptoglobin was measured in all dogs. The CIBDAI scores decreased during the treatment period in FRD and IBD (P &lt; 0.05). IGF-1 concentrations were positively correlated with body weight (BW) (r<sub>sp</sub> = 0.65, P &lt; 0.001) and values of IGF-1 were therefore normalized with BW. IGF-1/BW ratios were lower in FRD and IBD before treatment than in C (P &lt; 0.01). <br />IGF-1/BW ratios increased in FRD (P &lt; 0.05) dogs during treatment. Plasma glucose concentration was lower in FRD dogs before treatment than in C (P &lt; 0.05), and NEFA concentrations were higher in FRDdogs before and after treatment than in C (P &lt; 0.001). Haptoglobin concentrations were higher in IBD dogs before and after treatment than in all other groups (P &lt; 0.05). In conclusion, chronic enteropathies reduce the plasma IGF-1 status in dogs. The increase of the IGF-1/BW ratio after treatment suggests that plasma IGF-1 concentration may help to judge the outcome of chronic enteropathies in dogs.

scholarly journals Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study

2008 ◽  
Vol 158 (2) ◽  
pp. 229-237 ◽  
Author(s):  
Rob J van Geest ◽  
Inna V Sasim ◽  
Hans P F Koppeschaar ◽  
Rachel Kalmann ◽  
Simone N Stravers ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Severe Disease ◽  
Clinical Signs ◽  
Pulse Therapy ◽  
Controlled Study ◽  
Clinical Activity ◽  
Number Of Patients ◽  
Significant Difference ◽  
Graves Orbitopathy ◽  
Minor Criteria

ObjectiveTo assess whether methylprednisolone (MP) pulse therapy is efficacious in the treatment of moderately severe Graves' orbitopathy (GO).DesignProspective, placebo (PL)-controlled, double-blind, randomized study.MethodsFifteen previously untreated patients with active, moderately severe GO participated in the study; 6 patients received MP and 9 patients a PL. Moderately severe disease was defined using the NOSPECS classification of clinical signs of GO . Activity was measured with the clinical activity score (CAS). A dose of 500 mg MP or only solvent was administered intravenously, over three consecutive days, in four cycles at 4 weekly intervals (6 g of MP in total). Qualitatively, a successful treatment outcome was defined as an improvement in one major and/or two minor criteria in the worst eye at week 48. The major criteria were: improvement in diplopia grade; improvement in eye movement; a decrease in CAS of three points. The minor criteria were: decrease of eyelid retraction; decrease of proptosis; improvement in grade of soft tissue swelling; a decrease in CAS of two points.ResultsThe qualitative treatment outcome was successful at the end of the trial in five out of six (83%) patients receiving MP and in one out of nine (11%) patients given the PL (relative risk=7.5; (95% confidence interval 1.1–49.3), P=0.005). The treatment was well tolerated.ConclusionsIn spite of the small number of patients, a significant difference in outcome was observed between MP- and PL-treated patients. We conclude that MP pulse therapy appears to be an effective treatment for active, moderately severe GO.

scholarly journals Hierarchical modelling of immunoglobulin coated bacteria in dogs with chronic enteropathy shows reduction in coating with disease remission but marked inter-individual and treatment-response variability

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255012
Author(s):  
Lina María Martínez-López ◽  
Alexis Perez-Gonzalez ◽  
Elizabeth Ann Washington ◽  
Andrew P. Woodward ◽  
Alexandra Jazmin Roth-Schulze ◽  
...  
Keyword(s):  
Gastrointestinal Disease ◽  
Clinical Signs ◽  
Controlled Study ◽  
Gastrointestinal Microbiota ◽  
Chronic Enteropathy ◽  
Disease States ◽  
Faecal Samples ◽  
Chronic Enteropathies ◽  
Immunogenic Properties ◽  
Bacterial Groups

Chronic enteropathies are a common problem in dogs, but many aspects of the pathogenesis remain unknown, making the therapeutic approach challenging in some cases. Environmental factors are intimately related to the development and perpetuation of gastrointestinal disease and the gut microbiome has been identified as a contributing factor. Previous studies have identified dysbiosis and reduced bacterial diversity in the gastrointestinal microbiota of dogs with chronic enteropathies. In this case-controlled study, we use flow cytometry and 16S rRNA sequencing to characterise bacteria highly coated with IgA or IgG in faecal samples from dogs with chronic enteropathy and evaluated their correlation with disease and resolution of the clinical signs. IgA and IgG-coated faecal bacterial counts were significantly higher during active disease compared to healthy dogs and decreased with the resolution of the clinical signs. Characterisation of taxa-specific coating of the intestinal microbiota with IgA and IgG showed marked variation between dogs and disease states, and different patterns of immunoglobulin enrichment were observed in dogs with chronic enteropathy, particularly for Erysipelotrichaceae, Clostridicaceae, Enterobacteriaceae, Prevotellaceae and Bacteroidaceae, families. Although, members of these bacterial groups have been associated with strong immunogenic properties and could potentially constitute important biomarkers of disease, their significance and role need to be further investigated.

scholarly journals Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study

2019 ◽  
Vol 16 (5) ◽  
pp. 809 ◽  
Author(s):  
Hye-Jeong Park ◽  
Dhananjay Yadav ◽  
Da-Jeong Jeong ◽  
Suk-Jeong Kim ◽  
Myung-Ae Bae ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Repeated Measures ◽  
Controlled Study ◽  
Short Term ◽  
Repeated Measures Anova ◽  
Double Blinded ◽  
Lipid Parameters ◽  
Healthy Participants ◽  
Peripheral Blood Pressure ◽  
Group Comparisons

The current study was designed to investigate the short-term effects of policosanol consumption on blood pressure (BP) and the lipid parameters in healthy Korean participants with prehypertension. A total of 84 healthy participants were randomly allocated to three groups receiving placebo, 10 mg of policosanol, or 20 mg of policosanol for 12 weeks. Based on an average of three measurements of peripheral BP, the policosanol 20 mg group exhibited the most significant reduction, that is, up to 7.7% reduction of average systolic BP (SBP) from 136.3 ± 6.1 mmHg (week 0) to 125.9 ± 8.6 mmHg (week 12, p < 0.001). Between group comparisons using repeated measures ANOVA showed that the policosanol 20 mg group had a significant reduction of SBP at 12 weeks (p = 0.020) and a reduction of diastolic BP (DBP) at 8 weeks (p = 0.041) and 12 weeks (p = 0.035). The policosanol 10 mg and 20 mg groups showed significant reductions in aortic SBP of 7.4% and 8.3%, respectively. The policosanol groups showed significant reductions of total cholesterol (TC) of 9.6% and 8.6% and low-density lipoproteins (LDL-C) of 21% and 18% for 10 mg and 20 mg of policosanol, respectively. Between group comparisons using repeated measures ANOVA showed that the policosanol (10 mg and 20 mg) groups at 12 weeks had a significant reduction of TC (p = 0.0004 and p = 0.001) and LDL-C (p = 0.00005 and p = 0.0001) and elevation of %HDL-C (p = 0.048 and p = 0.014). In conclusion, 12-week consumption of policosanol resulted in significant reductions of peripheral SBP and DBP, aortic SBP and DBP, mean arterial pressure (MAP), and serum TC and LDL-C with elevation of % HDL-C.

scholarly journals Investigation of the efficacy of a dietetic food in the management of chronic enteropathies in dogs

2019 ◽  
Vol 186 (1) ◽  
pp. 26-26 ◽  
Author(s):  
Camilla Tørnqvist-Johnsen ◽  
Susan Campbell ◽  
Adam Gow ◽  
Nick X Bommer ◽  
Silke Salavati ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Activity Index ◽  
Significant Proportion ◽  
Clinical Signs ◽  
Disease Activity Index ◽  
Dietary Treatment ◽  
Response To Therapy ◽  
Dietary Therapy ◽  
Chronic Enteropathies ◽  
Dietetic Food

BackgroundChronic enteropathies (CEs) are a common cause of morbidity in dogs. CEs are diagnosed in dogs with chronic gastrointestinal clinical signs (>3 weeks), inflammatory changes on intestinal biopsies and where no other underlying cause is determined based on a thorough, standardised diagnostic work-up. Based on response to therapy, CEs are subclassified into food-responsive, antibiotic-responsive or steroid-responsive enteropathies. A significant proportion of dogs with a CE are food-responsive; however, there are limited peer-reviewed publications describing the clinical efficacy of the commercially available diets used to treat CE.MethodsIn this study, the authors evaluated the response of 15 dogs with a CE to a commercially available dietetic food (Hill’s Prescription Diet i/d Sensitive Canine Dry). The dogs underwent a standard diagnostic evaluation and did not receive concurrent anthelmintic, antibiotic, glucocorticoid or gastroprotectant therapies. The clinical efficacy of the dietary treatment was assessed by comparing the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) before and a median of 13 days after dietary therapy.ResultsThe authors found that the CIBDAI significantly decreased following the introduction of the dietetic food (median CIBDAI score pretreatment 9, post-treatment 2; P<0.0005).ConclusionThis study demonstrates that this dietetic food can be used to successfully manage CE in dogs.

Sign in / Sign up

Export Citation Format

Share Document